Search
for
Sort by
Research 61–90 of 1000+
- Summation and recommendations for the safe and effective use of topical and oral minoxidil
- Allergic Contact Dermatitis of the Scalp Associated With Scalp Applied Products: A Systematic Review of Topical Allergens.
- The role of platelet-rich plasma therapy in refractory folliculitis decalvans
- The Effects of Smoking on Hair Health: A Systematic Review
- Alopecia areata
- 62823 Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Premature hair graying: a multifaceted phenomenon
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- A Systematic Review: Application of Rice Products for Hair Growth
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Hair Follicle Melanogenesis Reflected in Hair Pigmentation as a Developmental Factor in Alopecia Areata
- The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
- The use of phosphodiesterase inhibitors for the treatment of alopecia
- The Immunological Association between Alopecia Areata and Respiratory Diseases: A Systematic Review
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
- Exosomes
- In Vivo Imaging Techniques for the Human Scalp: A Systematic Review of the Literature
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- Baricitinib as the first systemic treatment for severe alopecia areata
- Epidemiology of alopecia areata in Hispanic/Latinx patients
- COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
- Coconut, Castor, and Argan Oil for Hair in Skin of Color Patients: A Systematic Review.
- Not just thinning: A case of alopecia universalis after mild COVID-19
- Botulinum Toxins in Medical and Cosmetic Dermatology
- Characterizing hair loss in the elderly: an observational study of 163 patients